Development And Evaluation Of Docetaxel Encapsulated Nanoparticles From Poly(3 Hydroxybutyrate-Co-4-Hydroxybutyrate) Biopolymer

Simple item page
dc.contributor.authorAhmad Fisol, Faisalina
dc.date.accessioned2017-10-20T07:34:00Z
dc.date.available2017-10-20T07:34:00Z
dc.date.issued2012-10
dc.description.abstractThree types of nanoparticles (NPs) loaded with poorly water soluble anticancer drug, docetaxel (DCX), were developed in this research using poly 3-hydroxybutyrate-co-4-hydroxybutyrate P(3HB-co-4HB) biodegradable polymers. The optimized P(3HB-co-4HB) nanoparticles formulation was developed by screening the use of different tensioactives (PVA, lecithin, pluronic F-68 and vitamin E TPGS) in modified emulsion/solvent evaporation and nanoprecipitation production methods. From all the experiments carried out, it was found that P(3HB-co-4HB) nanoparticles with good physicochemical characteristics (particle size <200 nm, PDI <0.15 and zeta potential -10 mV) were prepared with emulsion/solvent evaporation method without problems such as particle agglomeration and precipitation of the polymer. The blank and DCX loaded nanoparticles were then characterized for their size and size distribution, surface charge, and morphology. DCX loaded P(3HB-co-70% 4HB) nanoparticles gave the best results with particles size of 140-180 nm with low PDI of 0.09. The surface charge of the nanoparticles was between -10mV and -22mV. Furthermore the encapsulation efficiencies result showed that at 30% of drug to polymer ratio, DCX loaded P(3HB-co-16% 4HB) NPs were able to encapsulate up to 42% of DCX; DCX loaded P(3HB-co-30% 4HB) NPs encapsulated up to 46% of DCX and DCX loaded P(3HB-co-70% 4HB) NPs encapsulated up to 50% of DCX in the nanoparticles system. From these results DCX loaded P(3HB-co-70% 4HB) NPs were chosen for the release experiments and two release behaviours were observed. P(3HB-co-70%4HB) nanoparticles with high drug/polymer ratio led to a relatively rapid release, while nanoparticles with drug to polymer ratio lower than 30% DCX amount in P(3HB-co-70%4HB) nanoparticles showed a prolonged drug release profile. 60% of DCX was released from the DCX-P(3HB-co-70% 4HB) NPs within 8 hr to 7 days for 5% , 10% and 20% of DCX/ P(3HB-co-70% 4HB) ratio while the 30% and 40% of DCX/ P(3HB-co-70% 4HB) ratio, NPs gave an almost complete drug release (98%) after 7 days of incubation.en_US
dc.identifier.urihttp://hdl.handle.net/123456789/5032
dc.language.isoenen_US
dc.publisherUniversiti Sains Malaysiaen_US
dc.subjectAnticancer Drugen_US
dc.subjectDocetaxel (DCX)en_US
dc.titleDevelopment And Evaluation Of Docetaxel Encapsulated Nanoparticles From Poly(3 Hydroxybutyrate-Co-4-Hydroxybutyrate) Biopolymeren_US
dc.typeThesisen_US
Files
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Pusat Racun Negara - Tesis